23 December 2022 -  Based on landmark ZUMA-7 study, patients with LBCL treated with Yescarta in second-line achieved four-fold greater improvement in event-free survival of 8.3 months versus two months for standard care.

Kite Pharma and Daiichi Sankyo today jointly announced that the Japan Ministry of Health, Labour and Welfare has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma: diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

Read Daiichi Sankyo press release